[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"neurological-complication\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:neurological-complication":29},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,3,0,[8,45,75],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":4,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":33,"lastUpdatePostDateStruct":34,"startDateStruct":37,"completionDateStruct":39,"leadSponsor":41,"locationsCount":44},"100617884","comparison-of-ultrasound-cerebral-perfusion-imaging-with-routine-perfusion-ct-100617884",false,"NCT07324421","Comparison of Ultrasound Cerebral Perfusion Imaging With Routine Perfusion CT","Prospective Monocentric Study Comparing Cerebral Perfusion Parameters From an ULtrasonic Imaging System With Measures Provided by Clinical Routine Perfusion CT","SCULPT","Inclusion Criteria:\n\n* Patient ≥ 18 years old\n* Patient Informed Consent, or from his\u002Fher relative if the patient is not conscious and able to consent\n* Admission to ICU or CCU with indication to perform at least one CTP\n* Affiliated with or benefiting from a social security scheme\n* The subject's current clinical status, as assessed by medical history, physical examination, and\u002For relevant tests, indicates that they do not require immediate medical treatment or emergency care at the time of enrolment.\n\nExclusion Criteria:\n\n* Guardianship, curatorship or any deprivation of liberty by judicial or administrative decision\n* Pregnant or breast-feeding women\n* Known contra-indication or hypersensitivity to SonoVue® (to sulfur hexafluoride microbubbles or to one of its excipients such as polyethylene glycol (PEG))\n* Right-to-left shunts\n* Patients who have undergone craniectomy in the temporal region\n* Patients with open wounds or recent scars in the temporal region\n* Unstable hemodynamic or respiratory state contraindicating transportation to CTP scanner","ALL","18 Years",{"count":20,"type":21},50,"ESTIMATED","INTERVENTIONAL",[24],"NA","The primary goal of neurocritical care is to prevent secondary brain injury, which worsens neurological outcomes. Because clinical monitoring is often insufficient due to the patient's condition and medical treatments, multimodal monitoring using biophysical, electrophysiological, and imaging data is essential. In patients with subarachnoid hemorrhage (SAH), the most frequent and severe complication is delayed cerebral ischemia, often linked to arterial vasospasm and potentially leading to infarction. Early diagnosis combines transcranial Doppler (TCD), sensitive to vasospasm, with perfusion CT (CTP), which measures cerebral perfusion; this approach guides therapy and improves prognosis. Ultrasound, especially when enhanced with contrast agents (CEUS), allows non-invasive, bedside, repeated visualization of cerebral blood flow and perfusion-even through the skull. Agents like SonoVue® help quantify perfusion using time-intensity curves. The study aims to assess whether cerebral perfusion measurements from the SYLVER device are equivalent to those from CTP in ICU or CCU patients.",[27,28,29,30,31],"Neuro ICU","Sub Arachnoid Hemorrhage","Neurological Complication","Cerebral Ischemia","Brain Injuries, Vascular","RECRUITING","2025-12-23",{"date":35,"type":36},"2026-01-07","ACTUAL",{"date":38,"type":36},"2025-10-25",{"date":40,"type":21},"2026-08-15",{"name":42,"class":43},"Resolve Stroke","INDUSTRY",1,{"id":46,"slug":47,"hasResults":11,"nctId":48,"briefTitle":49,"officialTitle":50,"acronym":51,"eligibilityCriteria":52,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":53,"enrollmentInfo":54,"targetDuration":4,"studyType":22,"phases":56,"briefSummary":58,"conditions":59,"keywords":60,"overallStatus":64,"whyStopped":4,"lastUpdateSubmitDate":65,"lastUpdatePostDateStruct":66,"startDateStruct":68,"completionDateStruct":70,"leadSponsor":72,"locationsCount":44},"100560601","phase-2-evaluation-of-the-safety-and-efficacy-of-parecoxib-in-patients-with-subarachnoid-hemorrhage-100560601","NCT06579274","Evaluation of the Safety and Efficacy of Parecoxib in Patients With Subarachnoid Hemorrhage","A Randomized, Placebo-controlled, Double-blind Clinical Trial Evaluating the Safety and Efficacy of Parecoxib in Hospitalized Patients With Spontaneous Subarachnoid Hemorrhage","PARISAH","Inclusion Criteria:\n\n* Signed informed consent\n* Age: 18-85 years\n* Weight\\> 50 kg\n* Spontaneous SAH diagnosed on a native CT brain max. 48 hours after the first symptoms\n* Spontaneous SAH caused by rupture of the cerebral aneurysm confirmed on DSA or CT angiography (Fisher grade 1 to 4) OR Spontaneous SAH without a source on CT AG, DSA or MRI with Fisher grade 3 and 4\n* For women capable of becoming pregnant (see definitions from the CTFG guideline for contraception): use of the following highly reliable contraceptive method within 3 months after the end of the study: adherence to sexual abstinence or contraception containing progesterone with inhibition of ovulation (oral administration, injection) or non-hormonal intrauterine device or hormonal or bilateral tubal occlusion or partner vasectomy. Males: adherence to sexual abstinence or use of an adequate contraceptive method (i.e. condom) in case of sexual intercourse within 3 months after the end of the study.\n\nExclusion Criteria:\n\n* Symptoms of SAH without the finding of blood on the initial native CT scan of the brain\n* SAH from a cause other than a ruptured aneurysm, e.g. A-V malformation, traumatic SAH\n* Pregnancy and breastfeeding (pregnancy test)\n* Known hypersensitivity to the components of the product\n* Allergic reaction to the active substance or sulfonamides in the anamnesis\n* Concomitant treatment with other non-steroidal anti-inflammatory drugs, aspirin or corticosteroids (at least five half-lives before administration of the medicinal product under investigation)\n* Severe hepatic insufficiency (serum albumin level \\\u003C25 g\u002Fl or Child-Pugh score less than 10).\n* Active peptic ulcer or bleeding from the gastrointestinal tract in the anamnesis\n* Inflammatory bowel disease in the anamnesis\n* Congestive heart failure (NYHA II-IV) in history.\n* Proven ischemic heart disease, peripheral arterial insufficiency.\n* Participation in another clinical study (a gap of at least five half-lives before administration of the medicinal product under investigation).","85 Years",{"count":55,"type":21},112,[57],"PHASE2","Because of the important role of inflammation in the pathophysiology of SAH, it was hypothesized that its pharmacological manipulation might improve the prognosis of patients. In recent years, the effects of several groups of anti-inflammatory drugs on the development of complications after SAH have been described. Initially promising, glucocorticoids, thought to reduce cerebrovascular inflammation, brain swelling, and headache, failed in clinical trials. Studies have not provided clear evidence of the beneficial effects of these drugs in patients after SAH. Therefore, the administration of glucocorticoids is not currently part of the recommended practice. In addition, glucocorticoid treatment is associated with adverse effects that worsen outcomes, including hyperglycemia, infection, and the risk of gastrointestinal bleeding.",[29],[61,62,63],"subarachnoidal hemorrhage","inflammation","NSAIDs","NOT_YET_RECRUITING","2024-08-26",{"date":67,"type":36},"2024-08-30",{"date":69,"type":21},"2025-01-01",{"date":71,"type":21},"2027-07-01",{"name":73,"class":74},"St. Anne's University Hospital Brno, Czech Republic","OTHER",{"id":76,"slug":77,"hasResults":11,"nctId":78,"briefTitle":79,"officialTitle":80,"acronym":81,"eligibilityCriteria":82,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":83,"targetDuration":4,"studyType":85,"phases":4,"briefSummary":86,"conditions":87,"keywords":4,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":88,"lastUpdatePostDateStruct":89,"startDateStruct":91,"completionDateStruct":93,"leadSponsor":95,"locationsCount":44},"100504048","transcranial-doppler-optic-nerve-envelope-diameter-and-quantitative-pupillometry-measurements-100504048","NCT05843214","Transcranial Doppler, Optic Nerve Envelope Diameter and Quantitative Pupillometry Measurements","Transcranial Doppler, Optic Nerve Envelope Diameter and Quantitative Pupillometry Measurements in Postoperative Resuscitation Neurosurgery","DOPPLER","Inclusion Criteria:\n\n* Regulated intracranial surgery: scheduled \\> 48 hours\n* French-speaking patient\n* No opposition from the patient or a relative when the patient is unable to consent\n\nExclusion Criteria:\n\n* Chronic subdural haematoma\n* Isolated cerebral endovascular procedure\n* Stereotactic biopsy\n* Scheduled ventriculoperitoneal shunt or isolated ventriculocisternostomy\n* Specific non-inclusion criteria for quantitative pupillometry: known pupillary abnormalities, glaucoma, cataract surgery and any ocular surgery.",{"count":84,"type":21},230,"OBSERVATIONAL","Non-invasive neuromonitoring tools such as transcranial doppler, optic nerve envelope diameter measurement and quantitative pupillometry are routinely used in acute brain injured patients as part of multimodal neuromonitoring with the aim, among others, of detecting episodes of intracranial hypertension, each method allowing the study of one of the different pathophysiological mechanisms of its impact.\n\nHowever, at present there is no data in the literature on the value of these non-invasive neuromonitoring tools in the management of patients undergoing controlled intracranial surgery.\n\nThe study aims to help the early detection of postoperative neurological deterioration.",[29],"2023-05-02",{"date":90,"type":36},"2023-05-06",{"date":92,"type":36},"2023-02-10",{"date":94,"type":21},"2026-06-09",{"name":96,"class":74},"Centre Hospitalier Universitaire de la Réunion"]